Tricida — Investor Presentation (January 2022)
33 slides from Tricida's investor presentation, Jan 10, 2022
Slide 1: Slowing the Progression of Chronic Kidney Disease: Tricida Investor Presentation
Slowing the Progression of Chronic Kidney Disease Tricida Investor Presentation January 2022 Exhibit 99.1
Slide 2: Forward Looking Statements
2 Forward Looking Statements Any statements contained in this presentation or made during the accompanying oral presentation that are not statements of historical facts are forward-looking statements as defined under the Federal securities laws. Examples of such statements include our plans, beliefs
Slide 3: Tricida Highlights
3 Tricida Highlights • The Unmet Need – Acid-base balance and retained acid fundamentally impact kidney disease • The In-House Discovered Compound – Veverimer could be the first and only therapy to slow CKD progression through binding and removing retained acid • The Outcomes Trial – VALOR-CKD is a
Slide 4: The Unmet Need
The Unmet Need There are no FDA-approved therapies to slow CKD progression through the treatment of metabolic acidosis in patients with CKD
Slide 5: Kidney Disease Impacts Acid-Base Balance
5 Daily Metabolism Kidney Disease Impacts Acid-Base Balance Which Is Critical to Maintain Normal Physiologic Function Kraut. Nat Rev Nephrol. 2010;6(5):274; KDIGO Clinical Practice Guidelines 2012. Diseased Kidneys Lose Capacity to Excrete Acid Acid is generated from dietary sources and daily metabo
Slide 6: Persistent Acid Retention and Sustained Expression of ET-1, Aldosterone and Angiotensin
6 Laghmani K et al., J Clin Invest 107:1563-9, 2001. Wesson DE, J Am Soc Nephrol 12:1826-35, 2001. Wesson DE et al., Kidney Int 78:1128-35, 2010. Wesson DE et al., Kidney Int 82:1184-94, 2012. Wesson DE et al., Nephrol Dial Transplant 30:762-70, 2015. Phisitkul S et al., Kidney Int 77:617-23, 2010.
Slide 7: Retained Acid Results in Muscle Wasting and Bone Demineralization
7 Retained Acid Results in Muscle Wasting and Bone Demineralization Kraut 2017; Raphael 2018; Wang 2014; Rajan 2008; Stitt 2004; Amodu 2016; Kestenbaum 2020. Figure adapted from Kraut 2017. Bone DemineralizationMuscle Wasting Acid Retention Systemic pHMuscle pH Pro-Inflammatory Cytokines Insulin / I
Slide 8: Persistent Acid Retention Can Result in Serious Health Consequences
8 Persistent Acid Retention Can Potentially Result in Serious Health Consequences Acid Buffering Leads to Increased Protein Catabolism Muscle Wasting, Reduced Physical Functioning Acid Buffering Leads to Loss of Bone Density Increased Risk of Fractures, Renal Osteodystrophy Reduced Renal Acid Secret
Slide 9: No FDA-Approved Therapies to Slow CKD Progression Through Treating Metabolic Acidosis
9 Despite the High Unmet Need, There Are No FDA-Approved Therapies to Slow CKD Progression Through the Treatment of Chronic Metabolic Acidosis * Represents patients with Stages 1-5 CKD and metabolic acidosis. Data on file: 2019 US Census data, USRDS 2020 Annual Report, KDIGO 2012, Inker 2011. ** Bas
Slide 10: Prevalence of Metabolic Acidosis in CKD and Patients Treated by Physician Type
10 Prevalence of Metabolic Acidosis in Patients with CKD and Estimated Number of Patients Treated by Physician Type Focus on nephrologist-treated patients provides initial opportunity for veverimer Expansion to non-nephrologist- treated patients provides additional opportunity for veverimer Increase
Slide 11: Veverimer Potential First FDA-Approved Therapy for Metabolic Acidosis and CKD Progression
Veverimer has the potential to be the first and only FDA-approved therapy to treat metabolic acidosis and slow CKD progression
Slide 12: Veverimer: Designed to Bind and Remove Hydrochloric Acid
12GI: Gastrointestinal. HCl: Hydrochloric acid. *Veverimer’s maximum theoretical HCl binding capacity is approximately 10 mEq/gram. Excreted, resulting in removal of HCl* Binds protons (H+) and then selectively binds chloride (Cl–) in the GI tract Excretion in Feces O ra l I ng es tio n Ac id B in d
Slide 13: Veverimer Was Designed to Bind and Remove Acid in Patients with CKD
13 Veverimer Was Designed to Bind and Remove Acid in Patients with CKD Wesson DE, CJASN, 2021. Alpern RJ and Sakhaee K, AJKD, 1997. Klaerner G et al, J Pharmacol Exp Ther. 2020. Wesson DE et al, Lancet, 2019 Acid-Base Balance Is Impaired When Kidneys Are Unable to Fully Excrete Acid Load Veverimer B
Slide 14: Veverimer Clinical Development Program
14 Veverimer Clinical Development Program * Bushinsky 2018. **Wesson 2019. ***Wesson 2019. Completed Clinical Trials TRCA-101* 2-week, randomized, double-blind, placebo-controlled Phase 1/2 trial • 3 doses and 2 dosing regimens of veverimer or placebo • Blood bicarbonate endpoint • 135 subjects TRCA
Slide 15: TRCA-301 Serum Bicarbonate Increase and Time-to-Event Analyses
15 TRCA-301 Veverimer-Treated Subjects Experienced a Mean Increase from Baseline in Serum Bicarbonate of 4.5 mEq/L Tricida’s TRCA-301/301E Clinical Trials Have Advanced the Understanding of Metabolic Acidosis Veverimer is not yet approved by the FDA. BL: Baseline. W: Week. Error bars: Standard error
Slide 16: Summary of Past FDA Interactions and Goals for NDA Resubmission
16 Summary of Past FDA Interactions and Our Goals for Potential Resubmission of the Veverimer NDA • Submitted NDA for review through the Accelerated Approval Program • Received CRL August 2020 • Held End-of-Review Type A meeting with FDA Division of Cardiology and Nephrology October 2020 • Submitted
Slide 17: The VALOR-CKD Trial Design
The VALOR-CKD trial is designed to evaluate whether veverimer slows CKD progression in patients with metabolic acidosis and CKD
Slide 18: 2022 Focus: Execution and Completion of the VALOR-CKD Renal Outcomes Trial
18 2022 Focus: Execution and Completion of the VALOR-CKD Renal Outcomes Trial • Time-to-event, multicenter, randomized, double-blind, placebo-controlled trial • Primary endpoint: DD40, defined as time to first occurrence of renal death, ESRD or a confirmed ≥ 40% reduction in eGFR Veverimer QD (n~740
Slide 19: Tricida Will Gain Significant Information from the VALOR-CKD Trial
19 DD40 = renal death, end stage renal disease (ESRD), or ≥ 40% reduction in estimated glomerular filtration (eGFR). DD50 = death, ESRD, or ≥ 50% reduction in eGFR. KDQOL = kidney disease quality of life. CV = Cardiovascular. DXA = dual x-ray absorptometry. Tricida Will Gain Significant Information
Slide 20: Making Good Progress in Conducting our VALOR-CKD Renal Outcomes Trial
20 Making Good Progress in Conducting our VALOR-CKD Renal Outcomes Trial As of January 6, 2022, the VALOR-CKD trial has randomized over 1,480 subjects with an average treatment duration of ~21 months and has accrued 183 subjects with positively adjudicated primary endpoint events (renal death, ESRD,
Slide 21: VALOR-CKD Primary Endpoint Events Continue to Accrue on Track
21 VALOR-CKD Primary Endpoint Events Continue to Accrue on Track 183 Subjects with Primary Endpoint Events as of January 6, 2022 24 Additional Events Since the November 5, 2021, Third Quarter Financial Results Call Source: Inker et al. JASN 30:1735-1745, 2019, Data on event rates among 2197 control
Slide 22: VALOR-CKD Outlook for 2022
22 VALOR-CKD Outlook for 2022 * Refer to page 25 for powering assumptions. • Based on its financial runway, Tricida plans to stop the VALOR-CKD trial for administrative reasons in 2022 – Plan to stop prior to reaching the protocol specified 511 subjects with primary endpoint events – Now anticipate
Slide 23: Multiple Studies Show Treating Acid Retention Can Slow CKD Progression
23 Multiple Studies Have Provided Solid Evidence that Treating Acid Retention Can Slow CKD Progression
Slide 24: Key Findings from Studies on Treating Metabolic Acidosis to Slow CKD Progression
24 Key Findings from a Review of Studies Designed to Slow CKD Progression Through the Treatment of Metabolic Acidosis Author Lower Risk of CKD Progression Hazard Ratio de Brito-Ashurst, 2009 80% 0.20 Garneata, 2016 69% 0.31 Dubey, 2020 51% 0.49 Goraya and Wesson 2019. Limitations of these studies in
Slide 25: Powering Assumptions and Observed Hazard Ratios for Administrative Stop
25 Powering Assumptions and Observed Hazard Ratios for Stopping the VALOR-CKD Trial for Administrative Reasons True Hazard Ratio Administrative Stop at: 200 Events* 250 Events* 0.76 47% Power 56% Power 0.70 69% Power 78% Power 0.60 94% Power 97% Power 0.50 >99% Power >99% Power Observed hazard ratio
Slide 26: Positive VALOR-CKD Data Could Support NDA Re-submission and Expanded Program
Positive VALOR-CKD data has the potential to support an NDA re-submission and enable an expanded veverimer development program
Slide 27: Tricida Future Milestones and Potential NDA Resubmission
27 If positive, VALOR-CKD trial results could lead to a possible resubmission of the veverimer NDA with an anticipated 6-month review 4Q Tricida plans to initiate an administrative stop of the VALOR-CKD trial 3Q1Q Tricida Future Milestones 2Q 2022 Milestones 2023 Potential Milestones Anticipate repo
Slide 28: Positive VALOR-CKD Data Could Support an Expanded Veverimer Development Program
28 Positive VALOR-CKD Data Has the Potential to Support an Expanded Veverimer Development Program By the time a patient exhibits overt metabolic acidosis (i.e., serum bicarbonate levels < 22 mEq/L), damage from retained acid has already occurred. Treatment of retained acid with veverimer prior to ov
Slide 29: Clinical Development Strategy and Significant Opportunity in CKD
29 VALOR-CKD Ongoing trial Study inclusion: eGFR 20 to 40 and SBC 12 to 20 mEq/L VICTORY-CKD Future trial Study inclusion: eGFR 20 to 60 and SBC 12 to 24 mEq/L TRIUMPH-CKD Future trial Study inclusion: eGFR <90 and SBC <27 mEq/L SBC = serum bicarbonate. Source: Data on file. 2019 US Census data, USR
Slide 30: Robust Patent Portfolio for Veverimer Provides Protection Until 2038
30 • Several pending patent applications United States • Three issued EPO patents providing patent protection until 2034 and two issued patents providing protection until 2035 • Several pending EPO patent applications Europe Rest of World • Issued patents provide protection in numerous countries/reg
Slide 31: Financial Position
31 Financial Position • ~ $150.6 million cash, cash equivalents and investments as of December 31, 2021* • Debt includes $200 million of 3.50% Convertible Senior Notes due 2027 • ~ 55.4 million total shares outstanding as of December 31, 2021** * Unaudited. Anticipate reporting full Q4 2021 financia
Slide 32: Tricida Highlights
32 Tricida Highlights • The Unmet Need – Acid-base balance and retained acid fundamentally impact kidney disease – Significant opportunity to treat up to 4.3 million patients with metabolic acidosis and CKD in the US – Future opportunities based on the need for removal of retained acid in patients w
Slide 33: Thank You
THANK YOU Tricida Investor Presentation January 2022